Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Acute Rejection in Renal Transplant
NCT01117662Phase 3Terminated
- Sponsor
- Hannover Medical School
- Start
- May 2012
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in Acute Kidney Transplant Rejection (AR) (2 arms), sponsored by Hannover Medical School. Primary endpoint: Change of the Glomerular Filtration Rate at 1 year. Started May 2012; status: terminated.
02
Drugs
rituximab
03
Conditions
Acute Kidney Transplant Rejection (AR)
Beyond the preview
Go deeper on NCT01117662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01117662.